ArticleDiabetes, obesity & metabolism2026
Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the first Italian experience with teplizumab administered under a compassionate use programme for adults with Stage 2 type 1 diabetes (T1D), and to evaluate its feasibility, safety and early metabolic outcomes in a real-life clinical setting outside formal clinical trials. MATERIALS AND
methodsThree adult women (aged 20-40 years) with Stage 2 T1D, identified through islet autoantibody screening and dysglycaemia assessment, received a 14-day intravenous course of teplizumab (Tzield) in a day-hospital setting. Infusions were managed by a multidisciplinary team with standardised pre-medication and monitoring. Clinical and laboratory parameters (vital signs, lymphocyte count, liver enzymes, HbA1c, C-peptide, continuous glucose monitoring metrics) were recorded at baseline and after 3 months.
resultsTreatment was overall well tolerated. One patient developed mild transient elevation of transaminases and lymphopenia, resolving spontaneously. A second patient experienced a 40% reduction in lymphocyte count without symptoms. The third developed a mild cytokine-release syndrome on Day 5, which resolved with supportive therapy but led to treatment discontinuation due to anxiety. At 3-month follow-up, all patients maintained stable glycaemic control and preserved β-cell function.
conclusionsTeplizumab administration under compassionate use proved feasible and safe in a real-life academic context, consistent with pivotal trial data. The experience underscores the importance of a structured multidisciplinary approach, integrating endocrinologists, anaesthesiologists, nurses and psychologists to optimise adherence, safety and patient engagement during early disease-modifying immunotherapy in presymptomatic T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.